ClinicalTrials.gg
CompletedNCT07515209Updated Apr 7, 2026

A Clinical Study of HH-006 in Untreated Chronic Hepatitis B Virus Infected Patients

A Phase 1 interventional study of HH-006 and 0.9% normal saline in Chronic Hepatitis B Virus Infection, sponsored by Huahui Health. Completed at 3 sites in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Huahui Health · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 3 months after the study started (first participant enrolled Dec 2024, registered Mar 2026).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Enrollment
239th of 273
36 · median 120
Started
2024
with 33 others
Phase 1
50 of 375
16 open now
Registered
349th of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 239th largest by enrollment of the 273 interventional ones that give a count, is one of 34 that started in 2024, is one of 50 in phase 1, and was the 349th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled Phase I dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of multiple ascending doses (120 mg, 240 mg, 480 mg SC, QW×5) of HH-006 in untreated chronic HBV patients. Each cohort includes 12 participants (9 active, 3 placebo), with dose progression approved by a Safety Review Committee. Participants are monitored through 24 weeks post-dose. The study design allows for adjustments based on emerging data.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, multiple-dose escalation Phase I clinical study. The study aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary antiviral activity of multiple doses (120 mg QW, 240 mg QW, 480 mg QW, administered subcutaneously (S.C.) once weekly (QW) for 5 doses) in chronic hepatitis B virus (HBV) infected participants who are not receiving anti-HBV treatment, are HBeAg-negative or positive, have HBV DNA ≥ 100 IU/mL, 100 IU/mL \< HBsAg \< 5000 IU/mL, and ALT ≤ 5 × ULN.

Each dose cohort plans to enroll 12 participants, enrolled in batches according to the dose escalation principle. Participants will be randomized to receive either HH-006 (N=9) or placebo (N=3) for a repeated-dose (5 doses) tolerability and pharmacokinetic study.

Dosing for the next cohort will commence only after all 12 participants in the current dose cohort have completed the safety assessment up to 14 days post-last dose (Week 7, Day 43) and after review and approval by the Safety Review Committee. The currently planned maximum dose for escalation is 480 mg QW.

Each participant is planned to be followed up for 24 weeks after the last dose to assess the safety, tolerability, PK, immunogenicity, and preliminary antiviral activity of HH-006 in participants with chronic HBV infection. During the study, adjustments to the maximum dose, dosing regimen, blood sampling time points, and follow-up duration may be made based on the accumulating data obtained during the study.

Throughout the study, participants' safety indicators and virologic parameters will be closely monitored to evaluate the safety and antiviral activity of HH-006.

03

Conditions studied

  • Chronic Hepatitis B Virus Infection

Browse trials for

Keywords

  • chronic hepatitis B virus infection
  • safety
  • pharmacokinetics
  • antiviral activity
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18 to 60 years (inclusive);
  • Male weight ≥ 45 kg, female weight ≥ 40 kg, and (BMI, BMI = weight/height²): 18 kg/m² ≤ BMI ≤ 32 kg/m²;
  • positive for more than 6 months (including 6 months), and with 100 IU/mL \< HBsAg \< 5000 IU/mL prior to randomization;
  • HBV DNA ≥ 100 IU/mL prior to randomization;
  • ≤ 5 × prior to randomization;
  • No prior interferon antiviral therapy within 1 year before the screening period, and no prior treatment with nucleos(t)ide analogues within 6 months before the screening period;
  • Males not having undergone sterilization surgery and females not for less than two years must agree to use adequate and effective measures from screening until the last follow-up visit of the study (including hormonal contraceptives, intrauterine devices, cervical caps, or condoms);
  • Subjects must understand and comply with the study procedures, participate voluntarily, and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Females who are pregnant, breastfeeding, or have a positive pregnancy test at baseline with .
  • Co-infection with , syphilis, or .
  • History of alcoholic liver disease, non-alcoholic steatohepatitis, liver disease or other hereditary liver diseases, drug-induced liver disease, or other chronic liver diseases not caused by .
  • History of or concurrent progressive liver fibrosis or cirrhosis;
  • History of or concurrent hepatocellular carcinoma, or at screening: blood alpha-fetoprotein (AFP) ≥ 50 ng/mL; or imaging examinations such as liver ultrasound, CT, or MRI suggest possible hepatocellular carcinoma.
  • Clinically significant abnormalities;
  • Concurrent severe diseases of other systems or clinical conditions that, in the investigator's judgment, make the subject unsuitable for participation in this study:

Circulatory system diseases: e.g., unstable angina, myocardial infarction, congestive heart failure, etc.

Respiratory system diseases: e.g., severe (COPD), etc.

Primary or secondary renal diseases: e.g., chronic renal decompensation and renal diseases secondary to diabetes, hypertension, vascular diseases, etc.

Endocrine system diseases: e.g., poorly controlled diabetes or thyroid disease, etc.

Autoimmune diseases: e.g., systemic lupus erythematosus, primary thrombocytopenic purpura, rheumatoid arthritis, inflammatory bowel disease, sarcoidosis, autoimmune hemolytic anemia, severe psoriasis, etc.

Neuropsychiatric diseases: e.g., epilepsy, schizophrenia, etc. .

  • At screening: total > 1.1 × or direct bilirubin > 1.1 × ULN; \< 120 g/L (male) or \< 110 g/L (female); \< 100,000/mm³ (100 × 109/L); \< 1,500/mm³ (1.5 × 109/L); serum albumin \< 35 g/L; international normalized ratio (INR) > 1.3; estimated (eGFR, MDRD formula) \< 60 mL/min/1.73 m².
  • History of sustained alcohol consumption (average daily alcohol intake > 40 g for males, > 20 g for females) or illicit drug abuse within 6 months prior to screening (including the screening period).
  • Participation in any clinical trial of a drug (except for those who did not receive the drug) or medical device (except for non-invasive medical devices) within 3 months prior to screening, or being within 5 half-lives of a prior drug at the time of screening.
  • Significant trauma or major surgery within 3 months prior to screening.
  • Known allergy to antibody-based drugs or to any component of the investigational drug.
  • Individuals judged by the investigator to be unsuitable for participation in this study, or those with a close relationship to the study center: e.g., relatives of the investigator, affiliated personnel (e.g., staff or students of the study center).
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    HH-006

    Biological: HH-006

  • Placebo comparator
    Placebo

    Drug: 0.9% normal saline

Interventions

  • BiologicalHH-006

    120 mg, 240 mg, 480 mg subcutaneous QW, 5 doses

  • Drug0.9% normal saline

    1 mL, 2 mL, 4 mL subcutaneous QW, 5 doses

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs)

    Number of subjects with adverse events (AEs) and serious adverse events (SAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.

    Time frame: up to 24 weeks follow-up

  2. Clinically significant abnormalities

    Number of subjects with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v5.0.

    Time frame: up to 24 weeks follow-up

Secondary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve (AUC)

    AUC of HH-006 in plasma

    Time frame: up to 24 weeks follow-up

  2. Maximum Plasma Concentration (Cmax)

    Cmax of HH-006 in plasma

    Time frame: up to 24 weeks follow-up

  3. Time to Reach Maximum Plasma Concentration (Tmax)

    Tmax of HH-006 in plasma

    Time frame: up to 24 weeks follow-up

  4. Apparent Terminal Elimination Half-life (T1/2)

    T1/2 of HH-006 in plasma

    Time frame: up to 24 weeks follow-up

  5. Apparent Plasma Clearance (CL/F)

    CL/F of HH-006 in plasma

    Time frame: up to 24 weeks follow-up

  6. Immunogenicity: ADA

    Time frame: up to 24 weeks follow-up

  7. Antiviral Activity: Change in HBV DNA levels from baseline (at each study time point); Change in HBsAg levels from baseline (at each study time point)

    Time frame: up to 24 weeks follow-up

07

Study locations

3 sites
  • NanFang Hospital of Southern Medical University
    Guangzhou, Guangdong 510000, China
  • The Affiliated Panyu Central Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510000, China
  • The Eighth Affiliated Hospital of Guangzhou Medical University
    Guangzhou, Guangdong 510000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2024 to primary completion in Dec 2025, 11 months.

Of 73 industry-sponsored phase 1 interventional studies under Hepatitis B, Chronic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 26. This study's 11 months is below that.

Counting every sponsor, half of 81 studies reached it within 16 months; a quarter within 6 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 25, 2026
First posted
Apr 7, 2026
StartActual
Dec 20, 2024
Primary completionActual
Dec 15, 2025
CompletionActual
Dec 15, 2025
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07515209
Lead sponsor
Huahui Health
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Dec 20, 2024
Primary completion
Dec 15, 2025
Completion
Dec 15, 2025
Last update
Apr 7, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HH-006

Start the discussion